Introduction
============

Long-term excessive alcohol use can lead to numerous neurological complications including damage to the cerebral cortex,[@b1-ndt-12-2273] and impaired cognitive[@b2-ndt-12-2273] and neuropsychological functioning.[@b3-ndt-12-2273] Although these effects may be partially reversed after alcohol use ceases,[@b4-ndt-12-2273] a treatment that can augment brain recovery during the early stage of alcohol abstinence would be beneficial.

Repetitive transcranial magnetic stimulation (rTMS), a noninvasive neuromodulation technique, has been used as treatment for various neuropsychiatric disorders, including depression,[@b5-ndt-12-2273] obsessive--compulsive disorder,[@b6-ndt-12-2273] schizophrenia,[@b7-ndt-12-2273] and substance addiction.[@b8-ndt-12-2273] Modulation of the release of dopamine and glutamate in the mesolimbic dopaminergic system, a major pathway associated with substance-seeking behaviors, is a plausible mechanism underlying the effect of rTMS on addiction.[@b9-ndt-12-2273],[@b10-ndt-12-2273] The dorsolateral prefrontal cortex (DLPFC) has been shown to be associated with regulation of craving through the mesolimbic pathway.[@b11-ndt-12-2273] In randomized controlled trials, high-frequency rTMS over the right DLPFC was found to significantly reduce craving and stabilize cognitive performance in alcohol-dependent patients.[@b12-ndt-12-2273],[@b13-ndt-12-2273] DLPFC has also been shown to play a key role in memory function.[@b14-ndt-12-2273] Although studies have demonstrated that DLPFC rTMS is associated with enhancement of memory,[@b15-ndt-12-2273],[@b16-ndt-12-2273] few studies have evaluated the effect of DLPFC rTMS on memory in alcohol-dependent patients. We hypothesize that DLPFC rTMS could improve memory in alcohol-dependent patients who have recently undergone detoxification treatment.

Changes in levels of brain metabolites often precede abnormalities in brain structure, and proton magnetic resonance spectroscopy (^1^H-MRS) is a recognized method for quantifying such changes. ^1^H-MRS has been used to evaluate hippocampal brain metabolites in various populations, including patients with mild cognitive impairment,[@b17-ndt-12-2273] patients with Alzheimer's disease,[@b18-ndt-12-2273] cognitively normal older adults,[@b19-ndt-12-2273] and patients receiving whole brain radiotherapy.[@b20-ndt-12-2273] Results of these studies show hippocampal brain metabolites to be reliable preclinical markers of cognitive and memory function.

In this clinical trial, we aimed to investigate the effect of high-frequency DLPFC rTMS on memory in recently detoxified alcohol-dependent patients and evaluate the relationship between the effect and changes in levels of hippocampal brain metabolites as detected by ^1^H-MRS.

Materials and methods
=====================

Subjects
--------

This study was a single-center, randomized, double-blind, sham-controlled trial. Alcohol-dependent patients who were admitted to the Mental Health Institute of the First Hospital of Hebei Medical University from January 2011 to January 2012 were eligible for enrollment in this study. The inclusion criteria were as follows: 1) alcohol dependence in accordance with the diagnostic criteria of the International Classification of Diseases, 10th Revision, 2) Alcohol Dependence Scale score ≥14,[@b21-ndt-12-2273] 3) Clinical Institute Withdrawal Assessment of Alcohol Revised Scale[@b22-ndt-12-2273] (CIWA-Ar) score \<7, 4) right-handedness, and 5) ability to cooperate for cognitive function testing and magnetic resonance imaging (MRI). Patients were excluded if any of the following conditions were present: 1) Wernicke's encephalopathy, 2) Korsakoff syndrome, 3) schizophrenia, 4) intellectual disability, 5) history of cranial trauma or severe neurological diseases, 6) dependence on psychoactive substances (excluding tobacco), and 7) contraindication to rTMS. All patients provided written informed consent, and the study was approved by the Institution Review Board of the First Hospital of Hebei Medical University.

Patients were administered detoxification treatment consisting of oral diazepam 20--50 mg daily for 1--3 weeks. After the second week of alcohol detoxification, the patients were evaluated by two physicians and only those with a CIWA-Ar score \<7 were enrolled and included in the analyses. A total of 40 patients were enrolled and randomized to the experimental group or the control group using a random number table; patients with odd numbers were allocated to the experimental group and those with even numbers to the control group.

Intervention
------------

A Magstim RAPID2 stimulator (Magstim, Carmarthenshire, UK) equipped with a figure-8-shaped coil was used to deliver rTMS. Stimulation was administered over the right DLPFC. All patients received four treatment sessions. Duration of each treatment session was 5 days with a 2-day interval between sessions. During each session, patients received eight trains daily (10 Hz, 80% of resting motor threshold, 10 seconds on, 5 seconds off; 800 pulses). The control group was administered sham stimulation with the same parameters but with the coil placed perpendicular to the scalp.

Evaluation
----------

Evaluations were performed by two physicians, and the results were reviewed by the senior chief physician. Evaluators and the patients were unaware of group assignment.

Verbal and visuospatial episodic memory (immediate, delayed, and recognition for both) were assessed using the Hopkins Verbal Learning Test-Revised (HVLT-R)[@b23-ndt-12-2273] and Brief Visuospatial Memory Test-Revised (BVMT-R),[@b24-ndt-12-2273] respectively. ^1^H-MRS was used to detect bilateral hippocampal brain metabolites.

HVLT-R is a tool used to assess verbal learning and memory that requires recall of a list of 12 words (from three semantic categories) over three learning trials, free recall after a delay, and a recognition trial. BVMT-R is a common assessment for visual learning that requires patients to reproduce six figures at the correct location after a 10-second presentation. Each figure is scored a maximum of two points (one point for correct form, one point for correct location), and the total score over three trials is calculated.

For measurement of brain metabolites, MRI was performed on a GE Signa TwinSpeed 1.5T MRI (GE Healthcare, Buckinghamshire, UK), using three-dimensional spoiled gradient echo. Hippocampal volume was measured using coronal and sagittal planes. Point-resolved echo spin spectroscopy was utilized to collect single-voxel magnetic resonance spectra from the left and right sides. Shimming and water inhibition were automatically completed by the scanner, with a water suppression rate \>98%. Scanning was performed with the following parameters: repetition time =1,500 ms, echo time =35 ms, number of acquisitions =128, voxel size =20×20×20 mm, and acquisition time =3 minutes 48 seconds for each site. ^1^H-MRS was applied on bilateral hippocampi to detect *N*-acetyl aspartic acid (NAA), choline (Cho), and creatine (Cr). Image processing was performed at a workstation using vendor-provided software (GE-Funtool; GE Healthcare Bio-Sciences Corp.) to measure the levels of NAA, Cho, and Cr. As the Cr concentration remains relatively constant, its concentration was used as an internal reference for calculating the metabolite ratio (NAA/Cr and Cho/Cr).[@b25-ndt-12-2273]

Statistical analysis
--------------------

Continuous variables are presented as median with inter-quartile range, and categorical variables are presented as count with percentage. To compare the characteristics and outcomes between the two groups, Mann--Whitney *U*-test and chi-square tests were used for continuous and categorical variables, respectively. Cohen's *d* was calculated to compare the changes in HVLT-R and BVMT-R scores between the groups. Correlation between the percentage changes in memory function and measures of brain metabolites was tested by Spearman's rank correlation coefficient. A two-tailed *P*\<0.05 indicated statistical significance. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 19.0 (IBM Corporation, Armonk, NY, USA).

Results
=======

A total of 40 patients were enrolled in this study. Two patients in the experimental group were excluded due to being lost to follow-up; therefore, data from 18 patients in the experimental group and 20 patients in the control group were included in the analyses. There was no significant difference between the experimental and the control groups regarding median age (49 years vs 48 years, *P*=0.536), sex (male percentage: 66.7% vs 65.0%, *P*=0.914), or median duration of alcohol use (21.0 years vs 18.5 years, *P*=0.438).

Change in memory function after rTMS is presented in [Figure 1](#f1-ndt-12-2273){ref-type="fig"}. Both groups showed improvement in HVLT-R and BVMT-R scores from baseline. Improvement was significantly greater in the experimental group than the control group for both HVLT-R (change: 3.1 vs 1.7, *P*=0.003, Cohen's *d*=1.15) and BVMT-R (change: 6.0 vs 1.2, *P*\<0.001, Cohen's *d*=3.56).

Regarding changes in measurements of hippocampal brain metabolites, both groups exhibited bilateral increases in NAA/Cr and Cho/Cr after rTMS from baseline. The experimental group had significantly greater percentage change from baseline than the control group in NAA/Cr (left: 16.3% vs 5.7%, *P*=0.023; right: 28.7% vs 6.5%, *P*=0.001) and Cho/Cr (left: 26.7% vs 6.1%, *P*=0.005; right: 29.3% vs 6.8%, *P*\<0.001; [Table 1](#t1-ndt-12-2273){ref-type="table"}).

Correlations between the percentage change in memory function and the percentage change in brain metabolites are presented in [Table 2](#t2-ndt-12-2273){ref-type="table"}. In the left brain, the percentage change in BVMT-R significantly and positively correlated with the percentage change in NAA/Cr (*r*=0.324) and Cho/Cr (*r*=0.340). No significant correlation between HVLT-R and brain metabolites was noted in the left brain. In the right brain, the percentage change in both HVLT-R and BVMT-R showed significant positive correlation with the percentage change in both NAA/Cr and Cho/Cr ([Table 2](#t2-ndt-12-2273){ref-type="table"}).

No major adverse events were reported. Minor adverse events were reported in eight patients: five patients complained of headache (three in experimental group and two in control group) and three patients experienced dizziness (two in experimental group and one in control group). All adverse events resolved spontaneously.

Discussion
==========

In this study, treatment with high-frequency DLPFC rTMS was associated with improved memory in recently detoxified alcohol-dependent patients. Furthermore, improvement in memory positively correlated with increase in levels of brain metabolites, an indication of brain recovery. To the best of our knowledge, this is the first study to assess the effect of high-frequency DLPFC rTMS on memory and evaluate the correlation between the effect on memory and change in levels of hippocampal brain metabolites in this population.

The effects of DLPFC rTMS on craving reduction, mood modulation, and cognitive improvement in alcohol-dependent patients have been investigated in several studies. Mishra et al reported a significant reduction in alcohol craving in alcohol-detoxified patients following ten sessions of 10 Hz right DLPFC rTMS.[@b12-ndt-12-2273] In a follow-up study, the authors found similar significant reductions in craving when rTMS was administered over either the right or left DLPFC.[@b26-ndt-12-2273] Herremans et al found no effect on craving after one session of 20 Hz right DLPFC rTMS in detoxified alcohol-dependent patients. The author commented that the lack of effect may have resulted from inadequate stimulation.[@b27-ndt-12-2273] In a subsequent study, however, the authors found that a single session of 20 Hz right DLPFC rTMS was sufficient to significantly increase the stability of cognitive performance even without a reduction in craving.[@b13-ndt-12-2273] Furthermore, a study by Girardi et al reported significant reductions in both craving and depressive symptoms with 20 sessions of 20 Hz bilateral DLPFC rTMS as adjunctive therapy to standard drug treatment in concurrent alcohol-dependent patients with dysthymic disorder.[@b28-ndt-12-2273] In a study of bilateral DLPFC rTMS in patients with major depressive disorder with or without alcohol dependence, significant improvement in depressive symptoms was noted regardless of alcohol dependence.[@b29-ndt-12-2273] In our study, right DLPFC rTMS was associated with significant improvement in memory as assessed by HVLT-R and BVMT-R. The results provide further evidence for DLPFC rTMS as a potential treatment for improving memory and stabilizing cognitive performance in this population.

In this study, change in levels of bilateral hippocampal NAA, Cho, and Cr after DLPFC rTMS was evaluated using ^1^H-MRS. Previous studies have shown that hippocampal brain metabolites are useful preclinical predictors for cognitive decline and memory dysfunction.[@b19-ndt-12-2273] In a cross-sectional study, lower values of left hippocampal NAA/Cr were found to be significantly associated with poorer verbal learning (*r*=0.44) and memory retention (*r*=0.41) in older people suffering from long-term depression.[@b30-ndt-12-2273] In a prospective study, a significant decrease in hippocampal NAA level was noted after whole brain radiation, and left hippocampal NAA level was found to correlate with declined memory after radiotherapy.[@b20-ndt-12-2273] In the current study, degree of improvement in memory after high-frequency DLPFC rTMS was positively and significantly correlated with increase in hippocampal NAA/Cr and Cho/Cr. The results strongly support the positive effect of DLPFC rTMS on memory recovery in recently detoxified alcohol-dependent patients.

There were several limitations in this study. First is the limited number of patients enrolled in this study. Second, we did not control for some potential confounding factors, including body mass index, education level, and tobacco dependence. Third, as most participants reported that their drinking habits varied over time, amount of alcohol use could not be precisely assessed. Additionally, duration of alcohol use was self-reported, and recall bias is an inherent limitation of self-reported data. Finally, we did not evaluate craving; therefore, we could not evaluate the relationship between improvement in memory and learning and improvement in alcohol dependence.

Conclusion
==========

High-frequency DLPFC rTMS was associated with improvement in memory in recently detoxified alcohol-dependent patients, and the improvement was positively correlated with increase in levels of hippocampal brain metabolites. Further investigations in a greater number of patients are necessary to better explore the anticraving and memory-improving effects of this potentially beneficial treatment.
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![Change in memory function assessed by HVLT-R and BVMT-R after high-frequency right dorsolateral prefrontal cortex rTMS in recently detoxified alcohol-dependent patients.\
**Notes:** Both groups showed improved memory after rTMS from baseline. The experimental group had significantly greater improvement than the control group in HVLT-R (\**P*=0.003, Cohen's *d*=1.15) and BVMT-R (\*\**P*\<0.001, Cohen's *d*=3.56) scores.\
**Abbreviations:** rTMS, repetitive transcranial magnetic stimulation; HVLT-R, Hopkins Verbal Learning Test-Revised; BVMT-R, Brief Visuospatial Memory Test-Revised.](ndt-12-2273Fig1){#f1-ndt-12-2273}

###### 

The changes of brain metabolites after treatment

  Variables         Experimental group (n=18)   Control group (n=20)   *P*-value
  ----------------- --------------------------- ---------------------- -----------
  **Left brain**                                                       
  NAA                                                                  
   Pretreatment     55 (51--61)                 50 (46--56)            0.032
   Posttreatment    57 (49--62)                 52 (49--55)            0.065
   Change           3 (−3 to 6)                 2 (−1 to 3)            0.527
   Change (%)       5.5 (−5.8 to 9.7)           3.8 (−1.9 to 6.8)      0.804
  Cho                                                                  
   Pretreatment     52 (42--55)                 47 (44--51)            0.285
   Posttreatment    54 (50--63)                 49 (44--53)            0.005
   Change           7 (3--12)                   2 (−3 to 4)            0.004
   Change (%)       12.5 (5.5--25.9)            3.3 (−5.7 to 8.0)      0.004
  Cr                                                                   
   Pretreatment     45 (43--48)                 43 (41--46)            0.090
   Posttreatment    41 (39--43)                 43 (39--44)            0.371
   Change           −5 (−6 to −1)               −3 (−3 to 1)           0.017
   Change (%)       −8.8 (−13.9 to −2.4)        −5.3 (−7.5 to 1.2)     0.021
  NAA/Cr                                                               
   Pretreatment     1.2 (1.2--1.3)              1.2 (1.1--1.3)         0.292
   Posttreatment    1.4 (1.1--1.6)              1.3 (1.2--1.3)         0.077
   Change           0.2 (0.1--0.3)              0.1 (0--0.1)           0.017
   Change (%)       16.3 (8.3--26.7)            5.7 (1.4--12.1)        0.023
  Cho/Cr                                                               
   Pretreatment     1.1 (0.9--1.3)              1.1 (1.0--1.1)         0.930
   Posttreatment    1.4 (1.2--1.5)              1.1 (1.1--1.2)         0.001
   Change           0.3 (0.1--0.4)              0.1 (0--0.1)           0.003
   Change (%)       26.7 (4.6--40.6)            6.1 (−1.4 to 12.8)     0.005
  **Right brain**                                                      
  NAA                                                                  
   Pretreatment     54 (49--56)                 52 (47--55)            0.333
   Posttreatment    60 (57--65)                 54 (47--58)            0.000
   Change           7 (4--13)                   3 (−2 to 4)            0.001
   Change (%)       11.8 (7.8--27.7)            4.5 (−3.2 to 8.3)      0.002
  Cho                                                                  
   Pretreatment     49 (42--52)                 49 (42--53)            0.736
   Posttreatment    58 (53--64)                 48 (46--55)            0.004
   Change           10 (6--13)                  4 (1.0 to 6)           0.001
   Change (%)       22.9 (9.5--30.8)            7.8 (0.7--13.0)        0.003
  Cr                                                                   
   Pretreatment     46 (43--49)                 45 (42--48)            0.340
   Posttreatment    43 (40--45)                 44 (43--46)            0.268
   Change           −4 (−6 to 1)                0 (−3 to 2)            0.077
   Change (%)       −8.7 (−10.7 to 2.4)         −1.1 (−6.6 to 3.3)     0.047
  NAA/Cr                                                               
   Pretreatment     1.2 (1.0--1.2)              1.1 (1.0--1.2)         0.988
   Posttreatment    1.4 (1.2--1.6)              1.2 (1.1--1.3)         0.002
   Change           0.3 (0.1--0.4)              0.1 (0--0.1)           0.001
   Change (%)       28.7 (6.4--40.1)            6.5 (−1.5 to 10.1)     0.001
  Cho/Cr                                                               
   Pretreatment     1.0 (1.0--1.1)              1.1 (0.9--1.2)         0.599
   Posttreatment    1.4 (1.2--1.5)              1.1 (1.0--1.2)         0.001
   Change           0.3 (0.2--0.5)              0.1 (0--0.2)           \<0.001
   Change (%)       29.3 (14.6--45.6)           6.8 (−0.2 to 14.5)     \<0.001

**Note:** Data are presented as median (interquartile range).

**Abbreviations:** NAA, *N*-acetyl aspartic acid; Cho, choline compound; Cr, creatine compound.

###### 

Correlations between the percentage changes of memory function and the percentage change of brain metabolites by Spearman's rank correlation coefficient

  Variables     HVLT-R                                              BVMT-R
  ------------- --------------------------------------------------- ----------------------------------------------------
  Left brain                                                        
   NAA          0.045                                               0.138
   Cho          −0.027                                              0.354[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   Cr           −0.127                                              −0.254
   NAA/Cr       0.274                                               0.324[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   Cho/Cr       0.062                                               0.340[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
  Right brain                                                       
   NAA          0.345[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}   0.561[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   Cho          0.254                                               0.352[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   Cr           −0.311                                              −0.352[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   NAA/Cr       0.392[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}   0.532[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}
   Cho/Cr       0.405[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}   0.461[\*](#tfn3-ndt-12-2273){ref-type="table-fn"}

**Note:**

*P*\<0.05.

**Abbreviations:** HVLT-R, Hopkins Verbal Learning Test-Revised; BVMT-R, Brief Visuospatial Memory Test-Revised; NAA, *N*-acetyl aspartic acid; Cho, choline compound; Cr, creatine compound.
